OTC : BIOVF

Swedish Orphan Biovitrum AB (publ)

$49.028 USD

$0 (0.0%)

Volume
200
Average Volume
12
Market Capitalization
$17.03B
P/E Ratio
174.26
Dividend Yield
0.00%
Price Target
Year High
$49.03
Year Low
$28.94
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$0.70
Company Overview

OTC

Guido Oelkers

Drug Manufacturers - Specialty & Generic

Healthcare

BIOVF

1969

SE

USD

https://www.sobi.com

46 86 97 20 00

N/A

N/A

Liquidity Metrics

0.47

0.70

0.47

0.04

0.00

Sales & Valuation

$28.17B

5.54

3.95

23.91

19.40

Profitability

$1.38

$476.8M

3.18%

2.14%

3.54%

1.67%

P/E Metrics

174.26

-2.53

-2.53

Analyst Price Target & Rating

Neutral

3/5

1 Analysts

%

Poll Results

About Swedish Orphan Biovitrum AB (publ) (OTC:BIOVF) Stock

Operating under the ticker BIOVF, Swedish Orphan Biovitrum AB (publ) is a specialized biotechnology company dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products. Its primary therapeutic focus areas encompass hematology, immunology, and a range of genetic and metabolic disorders, with a commercial presence across Europe, North America, and other international markets. The company's diverse portfolio includes medications addressing critical conditions such as hemophilia B (Alprolix) and hemophilia A (Elocta), thrombocytopenia (Doptelet), hemophagocytic lymphohistiocytosis (Gamifant), and hereditary tyrosinemia type-1 (Orfadin). Additionally, it provides Kineret for multiple inflammatory diseases, including cryopyrin-associated periodic syndr ... ome, rheumatoid arthritis, and Still's disease, alongside Synagis for severe lower respiratory tract infections. Sobi's broader product range further comprises various other therapeutics like Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. Beyond its proprietary offerings, Sobi is involved in the development of drug substances for external partners, notably ReFacto AF/Xyntha for Pfizer, as well as advancing BIVV001 for hemophilia A and Nirsevimab, which targets respiratory syncytial virus. A key strategic collaboration exists with Apellis Pharmaceuticals Inc. for the co-development of pegcetacoplan, aimed at treating a spectrum of rare diseases, such as paroxysmal nocturnal hemoglobinuria. The company maintains its headquarters in Solna, Sweden.

Swedish Orphan Biovitrum AB (publ) (SWOBY) Q1 2026 Earnings Call Transcript

2026-04-28 11:21:43

Swedish Orphan Biovitrum AB (publ) (SWOBY) Q1 2026 Earnings Call Transcript

Frequently Asked Questions

What is the current Swedish Orphan Biovitrum AB (publ) (BIOVF) stock price?

Swedish Orphan Biovitrum AB (publ)(OTC:BIOVF) stock price is $49.028 in the last trading session. During the trading session, BIOVF stock reached the peak price of $49.028 while $28.935 was the lowest point it dropped to. The percentage change in BIOVF stock occurred in the recent session was 0.0% while the dollar amount for the price change in BIOVF stock was $0.

BIOVF's industry and sector of operation?

The OTC listed BIOVF is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of BIOVF?

Henrik Stenqvist | Chief Financial Officer
Lena Bjurner | Head of People & Communication
Gerard Tobin | Head of Investor Relations
Guido Oelkers | Chief Executive Officer & President
Sofiane Fahmy | Head of Europe

How many employees does BIOVF have?

Number of BIOVF employees currently stands at 1969. BIOVF operates from Tomtebodavägen 23A, Solna, None 112 76, SE.

Link for BIOVF official website?

Official Website of BIOVF is: https://www.sobi.com

How do I contact BIOVF?

BIOVF could be contacted at phone #46 86 97 20 00 and can also be accessed through its website. BIOVF operates from Tomtebodavägen 23A, Solna, None 112 76, SE.

How many shares of BIOVF are traded daily?

The average number of BIOVF shares traded daily for last 3 months was 12.

What is the market cap of BIOVF currently?

The market value of BIOVF currently stands at $17.03B with its latest stock price at $49.028